news-medical.net
Study explores microbiome reboot to prolong effect of Crohn's disease therapy
This study tests whether a ‘microbiome reboot’ — using exclusive enteral nutrition followed by fecal microbiome transfer — can make the beneficial microbiome changes last longer and help keep Crohn’s disease in remission.
People with Crohn’s disease (including pediatric patients), caregivers, gastroenterologists, and researchers interested in microbiome-based therapies and dietary interventions.
What To Know
Researchers at TUM and LMU studied how exclusive enteral nutrition (EEN) changes the gut microbiome and are launching a clinical study combining EEN with fecal microbiome transfer (FMT) capsules from screened healthy donors to try to prolong remission in Crohn’s disease.
In lab models, microbiomes pre-adapted with the EEN formula prevented inflammation in mice; non-adapted microbiomes did not. The human study will assess safety, feasibility, and whether FMT after EEN can stabilize or delay recurrence of inflammation.
Findings are based on laboratory and animal-model work and motivate a clinical study now underway. The article reports the planned human trial will test safety and feasibility; it does not present clinical outcomes in people yet.
Fecal microbiome transfer is an active research area with varying results across conditions; follow-up and peer-reviewed trial results will be needed before changing care.
